HIGHLIGHTS
- who: Fumihiro Kashizaki from the (UNIVERSITY) have published the Article: Efficacy of lorlatinib after alectinib-induced lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report, in the Journal: (JOURNAL)
- future: Evidence from future studies will help determine the optimal chemotherapy regimen after the onset of ALK-TKI-associated DILD.
SUMMARY
Inhibitors (ALK-TKIs) have been developed for treatment. ALK-TKIs are more effective than cytotoxic chemotherapy, and long-term treatment with TKIs has been shown to prolong the overall survival of patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.